Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Larynx preservation: nonsurgical approaches].

J Bourhis1, J L Lefebvre, S Temam

  • 1Département de radiothérapie, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France. bourhis@igr.fr

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|February 1, 2005
PubMed
Summary

Larynx preservation is achievable for early-stage cancers via surgery or radiotherapy. For advanced stages, combined chemotherapy and radiotherapy offer options, but induction chemotherapy requires careful patient selection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robotic Peritoneal Flap Revision Vaginoplasty: Step-by-Step Technique: Tips & Tricks.

International urogynecology journal·2026
Same author

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.

ESMO open·2026
Same author

Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

International guidelines for the delineation of the postoperative clinical target volumes (CTV) for parotid and submandibular gland cancers.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

[Proposal for the delineation of postoperative primary clinical target volumes in maxillary sinus and nasal cavity cancers].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024

Area of Science:

  • Oncology
  • Otolaryngology
  • Radiation Oncology

Background:

  • Larynx preservation is a key goal in managing laryngeal and hypopharyngeal cancers.
  • Maintaining laryngeal functions is crucial for patient quality of life.

Purpose of the Study:

  • To review strategies for larynx preservation in various stages of laryngeal and hypopharyngeal carcinoma.
  • To evaluate the efficacy and safety of different treatment modalities.

Main Methods:

  • Review of treatment approaches including partial surgery, radiotherapy, exclusive chemotherapy, and combined chemoradiotherapy.
  • Analysis of data from randomized trials investigating induction chemotherapy followed by local treatment.

Main Results:

Related Experiment Videos

  • Early-stage (T1-T2) cancers are manageable with partial surgery or radiotherapy.
  • Locally advanced (T2-T3) cancers benefit from radiotherapy, enhanced by modified fractionation or concurrent cisplatin-based chemotherapy.
  • Induction chemotherapy (cisplatin-5FU) followed by adapted local treatment shows promise but requires caution, especially in non-responders.

    • Conclusions:

    • Larynx preservation strategies vary by cancer stage.
    • Combined chemoradiotherapy and carefully selected induction chemotherapy offer viable larynx-sparing options for advanced disease.
    • T4 tumors with deep infiltration or cartilage/soft tissue invasion typically preclude larynx preservation.